Underlying Cause of Diabetic Peripheral Neuropathy Targeted in Gene Therapy Trial
VM BioPharma, the United States division of ViroMed Co., Ltd. in Seoul, Korea, announced the first patient was dosed in the recently initiated Phase 3 clinical study evaluating VM202, a proprietary DNA-based biopharmaceutical, in patients with painful diabetic peripheral neuropathy (DPN). This is the first pivotal gene therapy trial specifically targeting the most common cause …
Underlying Cause of Diabetic Peripheral Neuropathy Targeted in Gene Therapy Trial Read More »